Testosterone therapy in breast cancer survivors is an area of growing interest — and ongoing debate. In this session, Dr. Sarah Glynne will review the current data on testosterone use in women with a history of breast cancer, examining potential benefits, safety considerations, and areas of uncertainty. She’ll provide an evidence-informed framework to guide thoughtful clinical decision-making and patient counseling. Designed for clinicians navigating complex symptom management, this discussion will help translate evolving research into balanced, individualized care.
Sarah Glynne, MBChB, MRCOG, is an experienced GP and Menopause Specialist. Based at The Portland Hospital in London, she is trained to provide consultation in all aspects of menopause care and to support women with complex menopause-related health needs. She has a special interest in menopause care for women with a history of breast cancer.
Dr Glynne graduated from Imperial College School of Medicine with first-class Honours in Physiology (BSc), and distinctions in Pathology and Surgery. She undertook general medical training at Northwick Park Hospital and University College Hospital before switching to a career in General Practice in 2005. She is an accredited member of both the Royal College of Physicians and the Royal College of General Practitioners. In 2016, she completed a Master of Science (MSc) degree in allergy and immunology at Imperial College, passing her exams with distinction. Since 2020, her practice and academic interests have focused solely on menopause.
Dr. Glynne is active in research and has published extensively on clinical outcomes in women treated with hormone replacement therapy (HRT), including testosterone, and the role of HRT after breast cancer diagnosis. She co-authored two chapters in the 2025 book Principles of Precision Hormone Therapy for Healthy Aging. She contributed to the updated British Society of Sexual Medicine Position Statement on the Management of Genitourinary Syndrome of the Menopause (GSM). She served as a clinical advisor for the recently published NICE technology appraisal on the use of fezolinetant for the treatment of menopausal vasomotor symptoms (ID5071). She is currently working with Professor Jayant Vaidya, Professor of Breast Surgery and Oncology, setting up a clinical trial to study breast cancer and non-breast cancer outcomes in women who choose to take HRT after breast cancer (the Menopausal Hormone Therapy Outcomes After Breast Cancer trial, or MENO-ABC trial). More information about the study can be found here: https://www.londonbreastcancer.com/meno-abc-trial.
Dr. Glynne is passionate about teaching and education and has created several patient resources to support shared decision-making and patient-centered menopause care. She is a member of the British Menopause Society, The Menopause Society (aka the North American Menopause Society), and the International Menopause Society.